Arcus Biosciences RCUS 深 滬
等待開盤 12-25 09:30:00 美东时间
23.12
+0.410
+1.81%
華盛通- 最 高23.16
- 今 開22.83
- 成交量 44.48万股
- 最 低 22.53
- 昨 收 22.71
- 總市值 24.51亿
- 52周最高 26.40
- 市盈率 靜 --
- 換手率 0.42%
- 52周最低 6.50
- 委 比 16.96%
- 總股本 1.06亿
- 歷史最高 49.10
- 量 比 0.22
- 振 幅 2.77%
- 歷史最低 6.30
- 每 手 1
- 風險率 4.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TIGIT的转机还会出现吗？
文 | 氨基观察 被寄予“下一个免疫检查点”厚望的TIGIT，几乎走到了临床验证的尽头。 12月12日，Arcus Biosciences宣布其与吉利德合作研...
12-19 10:36
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
12-13 02:35
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a
12-12 21:33
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
12-11 23:17
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
12-01 14:33
B of A Securities Maintains Neutral on Arcus Biosciences, Raises Price Target to $26
B of A Securities analyst Jason Zemansky maintains Arcus Biosciences (NYSE:RCUS) with a Neutral and raises the price target from $17 to $26.
11-29 01:03
Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies Inc (NYSE:KEYS) rose sharply in pre-market trad...
11-25 18:50
Arcus Biosciences prices $250M offering
Clinical-stage, global biopharmaceutical company Arcus Biosciences (RCUS) priced an underwritten public offering of 13.7M shares at $18.25 per share. Gross proceeds are expected to be $250M. The under...
10-31 12:40
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
